Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial
- PMID: 31809439
- DOI: 10.1097/AOG.0000000000003620
Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial
Abstract
Objective: To estimate the efficacy and safety of mifepristone antagonization with high-dose oral progesterone.
Methods: We planned to enroll 40 patients in a double-blind, placebo-controlled, randomized trial. We enrolled patients at 44-63 days of gestation with ultrasound-confirmed gestational cardiac activity who were planning surgical abortion. Participants ingested mifepristone 200 mg and initiated oral progesterone 400 mg or placebo 24 hours later twice daily for 3 days, then once daily until their planned surgical abortion 14-16 days after enrollment. Follow-up visits were scheduled 3±1, 7±1, and 15±1 days after mifepristone intake with ultrasonography and blood testing for human chorionic gonadotropin and progesterone. Participants exited from the study when they had their surgical abortion or earlier for gestational cardiac activity absence, gestational sac expulsion, or medically indicated suction aspiration. We assessed the primary outcome of continued gestational cardiac activity at approximately 2 weeks (15±1 day), side effects after drug ingestion, and safety outcomes including hemorrhage and emergent treatment.
Results: We enrolled participants from February to July 2019 and stopped enrollment after 12 patients for safety concerns. Mean gestational age was 52.5 days. Two (one per group) voluntarily discontinued 3 days after mifepristone ingestion for subjective symptoms (nausea and vomiting, bleeding). Among the remaining 10 patients (five per group), gestational cardiac activity continued for 2 weeks in four in the progesterone group and two in the placebo group. One patient in the placebo group had no gestational cardiac activity 3 days after mifepristone use. Severe hemorrhage requiring ambulance transport to hospital occurred in three patients; one received progesterone (complete expulsion, no aspiration) and two received placebo (aspiration for both, one required transfusion). We halted enrollment after the third hemorrhage. No other significant side effects were reported.
Conclusion: We could not estimate the efficacy of progesterone for mifepristone antagonization due to safety concerns when mifepristone is administered without subsequent prostaglandin analogue treatment. Patients in early pregnancy who use only mifepristone may be at high risk of significant hemorrhage.
Clinical trial registration: ClinicalTrials.gov, NCT03774745.
Comment in
-
Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial.Obstet Gynecol. 2020 Apr;135(4):969-970. doi: 10.1097/AOG.0000000000003780. Obstet Gynecol. 2020. PMID: 32217951 No abstract available.
-
Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial.Obstet Gynecol. 2020 Apr;135(4):970. doi: 10.1097/AOG.0000000000003786. Obstet Gynecol. 2020. PMID: 32217952 No abstract available.
-
Mifepristone Antagonization With Progesterone to Prevent Medical Abortion: A Randomized Controlled Trial.Obstet Gynecol. 2020 Apr;135(4):970. doi: 10.1097/AOG.0000000000003781. Obstet Gynecol. 2020. PMID: 32217953 No abstract available.
-
In Reply.Obstet Gynecol. 2020 Apr;135(4):970-971. doi: 10.1097/AOG.0000000000003782. Obstet Gynecol. 2020. PMID: 32217954 No abstract available.
Similar articles
-
Low-dose mifepristone 200 mg and vaginal misoprostol for abortion.Contraception. 1999 Jan;59(1):1-6. doi: 10.1016/s0010-7824(98)00150-4. Contraception. 1999. PMID: 10342079 Clinical Trial.
-
Randomized, double-blind, controlled trial of mifepristone in capsule versus tablet form followed by misoprostol for early medical abortion.Eur J Obstet Gynecol Reprod Biol. 2004 Oct 15;116(2):211-6. doi: 10.1016/j.ejogrb.2003.12.024. Eur J Obstet Gynecol Reprod Biol. 2004. PMID: 15358467 Clinical Trial.
-
WHO multinational study of three misoprostol regimens after mifepristone for early medical abortion.BJOG. 2004 Jul;111(7):715-25. doi: 10.1111/j.1471-0528.2004.00153.x. BJOG. 2004. PMID: 15198763 Clinical Trial.
-
Medical methods for first trimester abortion.Cochrane Database Syst Rev. 2004;(2):CD002855. doi: 10.1002/14651858.CD002855.pub3. Cochrane Database Syst Rev. 2004. PMID: 15106180 Updated. Review.
-
Anti-progesterones for the interruption of pregnancy.Baillieres Clin Obstet Gynaecol. 1988 Sep;2(3):617-29. doi: 10.1016/s0950-3552(88)80048-8. Baillieres Clin Obstet Gynaecol. 1988. PMID: 3069265 Review.
Cited by
-
Medication Abortion and Abortion Pill Reversal: An Exploratory Analysis on the Influence of Others in Women's Decision-Making.Cureus. 2023 Dec 5;15(12):e49973. doi: 10.7759/cureus.49973. eCollection 2023 Dec. Cureus. 2023. PMID: 38179370 Free PMC article.
-
Mifepristone Antagonization with Progesterone to Avert Medication Abortion: A Scoping Review.Linacre Q. 2023 Nov;90(4):395-407. doi: 10.1177/00243639231176592. Epub 2023 May 29. Linacre Q. 2023. PMID: 37969420 Free PMC article.
-
Reversal of medication abortion with progesterone: a systematic review.BMJ Sex Reprod Health. 2024 Jan 9;50(1):43-52. doi: 10.1136/bmjsrh-2023-201875. BMJ Sex Reprod Health. 2024. PMID: 37863512 Free PMC article.
-
Progesterone-mediated reversal of mifepristone-induced pregnancy termination in a rat model: an exploratory investigation.Sci Rep. 2023 Jul 6;13(1):10942. doi: 10.1038/s41598-023-38025-9. Sci Rep. 2023. PMID: 37414825 Free PMC article.
-
Medication Abortion "Reversal" Laws: How Unsound Science Paved the Way for Dangerous Abortion Policy.Am J Public Health. 2023 Feb;113(2):202-212. doi: 10.2105/AJPH.2022.307140. Am J Public Health. 2023. PMID: 36652652 Free PMC article.
References
-
- Jones RK, Witwer E, Jerman J. Abortion incidence and service availability in the United States, 2017. Available at: https://www.guttmacher.org/report/abortion-incidence-service-availabilit.... Accessed October 8, 2019.
-
- Danco Laboratories, LLC. Mifeprex®. 2016. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/020687s020lbl.pdf. Accessed October 8, 2019.
-
- Spitz IM, Bardin CW. Mifepristone (RU 486)—a modulator of progestin and glucocorticoid action. N Engl J Med 1993;329:404–12.
-
- Mahajan DK, London SN. Mifepristone (RU486): a review. Fertil Steril 1997;68:967–76.
-
- Hsia JK, Lohr PA, Taylor J, Creinin MD. Medical abortion with mifepristone and vaginal misoprostol between 64 and 70 days' gestation. Contraception 2019;100:178–81.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
